Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.340
-0.010 (-0.43%)
At close: Mar 20, 2026, 4:00 PM EDT
2.330
-0.010 (-0.43%)
After-hours: Mar 20, 2026, 7:54 PM EDT
Editas Medicine Stock Forecast
Stock Price Forecast
The 6 analysts that cover Editas Medicine stock have a consensus rating of "Strong Buy" and an average price target of $4.92, which forecasts a 110.26% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $8.00.
Price Target: $4.92 (+110.26%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Editas Medicine stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Hold → Strong Buy Upgrades $8 | Hold → Strong Buy | Upgrades | $8 | +241.88% | Mar 10, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $3.5 | Strong Buy | Maintains | $3.5 | +49.57% | Mar 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +113.68% | Sep 5, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $3 → $4 | Hold | Maintains | $3 → $4 | +70.94% | Sep 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $5 | Strong Buy | Maintains | $3 → $5 | +113.68% | Aug 15, 2025 |
Financial Forecast
Revenue This Year
26.88M
from 40.52M
Decreased by -33.65%
Revenue Next Year
19.92M
from 26.88M
Decreased by -25.91%
EPS This Year
-1.16
from -1.80
EPS Next Year
-1.02
from -1.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 104.0M | 48.0M | |||
| Avg | 26.9M | 19.9M | |||
| Low | 6.9M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 156.5% | 78.5% | |||
| Avg | -33.7% | -25.9% | |||
| Low | -83.1% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.65 | -0.64 | |||
| Avg | -1.16 | -1.02 | |||
| Low | -1.55 | -1.29 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.